Cocrystal Pharma Inc./$COCP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
- Ticker
- $COCP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 10
- Headquarters
- Bothell, United States
- Website
- www.cocrystalpharma.com
COCP Metrics
BasicAdvanced
$20M
-
-$0.76
1.48
-
Price and volume
Market cap
$20M
Beta
1.48
52-week high
$2.03
52-week low
$0.76
Average daily volume
36K
Financial strength
Current ratio
1.237
Quick ratio
1.11
Long term debt to equity
0.947
Total debt to equity
1.284
Profitability
EBITDA (TTM)
-10.06
Gross margin (TTM)
-1,744.24%
Net profit margin (TTM)
-3,011.52%
Operating margin (TTM)
-3,063.64%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-96.07%
Return on equity (TTM)
-311.68%
Valuation
Price to revenue (TTM)
40.481
Price to book
13.47
Price to tangible book (TTM)
13.47
Price to free cash flow (TTM)
-1.677
Free cash flow yield (TTM)
-59.63%
Free cash flow per share (TTM)
-0.608
Growth
Earnings per share change (TTM)
-38.54%
10-year revenue growth (CAGR)
29.44%
3-year earnings per share growth (CAGR)
-30.57%
10-year earnings per share growth (CAGR)
-28.22%
What the Analysts think about COCP
Analyst ratings (Buy, Hold, Sell) for Cocrystal Pharma Inc. stock.
Analyst projections of the future price of Cocrystal Pharma Inc. stock.
COCP Financial Performance
Revenues and expenses
COCP Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.